Pramipexole as adjunct to haloperidol in schizophrenia

American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders (Third edition, revised) DSM-III-R. (1987) The American Psychiatric Association, Washington D.C. Benkert, O., Gründer, G. and Wetzel, H. (1992) Dopamine autoreceptor agonists in the treatment of schizophrenia and major depression. Pharmacopsychiatry 25, 254–260. Buchsbaum, M.S., Nuechterlein, K.H., Haier, R.J., Wu, J., Sicotte, N., Hazlett, E., Asarnow, R., Potkin, S. and Guich, S. (1990) Glucose metabolic rate in normals and schizophrenics during the continuous performance test assessed by positron emission tomography. Br. J. Psychiatry 156, 216–227. Chouinard, G. and Jones, B.D. (1979) Evidence of brain dopamine deficiency in schizophrenia. Can. J. Psychiatry 24, 661–667. Fleischhacker, W.W., Bergmann, K.J., Perovich, R., Pestreich, L.K., Borenstein, M., Lieberman, J.A. and Kane, J.M. (1989) The Hillside Akathisia Scale: A new rating instrument for neuroleptic-induced akathisia. Psychopharmacol. Bull. 2, 222–226. Ingvar, D.H. and Franzen, G. (1974) Abnormalities of cerebral blood flow distribution in patients with chronic schizophrenia. Acta Psychiatr. Scand. 50, 425–462. Kasper, S., Fuger, J., Zinner, H.J., Bäuml, J. and Möller H.J. (1992) Early clinical results with the neuroleptic roxindole (EMD 49980) in the treatment of schizophrenia — an open study. Eur. Neuropsychopharmacol. 2, 91–95. Kay, S.R., Opler, L.A. and Lindermayer, J.P. (1988) Reliability and validity of the Positive and Negative Syndrome Scale for schizophrenics. Psychiatry Res. 23, 99–110. Kissling, W., Mackert, A., Bäuml, J. and Lauter, H. (1992) Erste klinische Erfahrungen mit dem neuen Dopamin-Autorezeptoragonisten SND 919. In: Gaebel, W. and Laux, G. (Eds.) Biologische Psychiatrie. Synopsis 90/91. Springer, Berlin, pp. 256–249. Leblanc, G., Cormier, H.J., Vaillancourt, S., Gagne, M.A. and Gingras, C. (1990) Who are the patients treated in an outpatient clinic with high dosage neuroleptics? Can. J. Psychiatry 35 (1), 12–24. Lecrubier, Y., Puech, A.J., Simon, P. and Widlöcher, D. (1980) Schizophrénie: hyper ou hypofonctionnement du systéme dopaminergique? Une hypothése bipolaire. Psychol. Med. 12, 2431–2441. MacKay, A.V.P. (1980) Positive and negative schizophrenic symptoms and the role of dopamine. Br. J. Psychiatry 137, 379–383. McEvoy, J.P., Hogarty, G.E. and Steingard, S. (1991) Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose. Arch. Gen. Psychiatry 48, 739–745. Meltzer, H.Y. (1980) Relevance of dopamine autoreceptors for psychiatry: preclinical and clinical studies. Schizophr. Bull. 6, 456–475. National Institute of Mental Health. Clinical Global Impressions (1976). In: Guy, W. (Ed.) ECDEU Assessment Manual for Psychopharmacology, revised edition, Rockville, MD, pp. 217–222. Ohmori, T., Koyama, T., Inoue, T., Matsubara, S. and Yamashita, I. (1993) B-HT 920, a dopamine D2 agonist, in the treatment of negative symptoms of chronic schizophrenia. Biol. Psychiatry 33, 687–693. Olbrich, R. and Schanz, H. (1988) The effect of the partial dopamine terguride on negative symptoms in schizophrenics. Pharmacopsychiatry 21, 389–390. Palluk, R. (1995) Cardiovascular interactions of pramipexole and haloperidol after IV and SC administration in anaesthetised rabbits. Boehringer Ingelheim, U 95-2199, October 17, 1995. Schaefer, E., Bailey, P.E. and Koester, J. (1993) Double-blind, controlled clinical trial to compare the efficacy and tolerance of pramipexole and placebo in patients with residual schizophrenia. Boehringer Ingelheim, U 93-0608, June 25, 1993. Simpson, G.H. and Angus, G.S.W. (1970) A rating scale for extrapyramidal side effects. Acta Psychiatr. Scand. 212 (suppl.), 11–19. Tamminga, C.A., Schaffer, M.H. and Schmith, R.C. (1978) Schizophrenic symptoms improve with apomorphine. Science 200, 567–568. Weinberger, D.R., Bermann, K.F. and Zec, R.F. (1986) Physiological dysfunction of dorsolateral prefontal cortex in schizophrenia: (I) Regional cerebral blood flow (RCBF) evidence. Arch. Gen. Psychiatry 43, 114–124. White, F.J. and Wang, R.Y. (1984) A10 dopamine neurones: role of autoreceptors in determining firing rate and sensitivity to dopamine agonists. Life Sci. 34, 1161–1170.